More than 10 pre-profit drug developers are seeking Hong Kong listings as AI-powered biotech platforms draw growing investor ...

The AI drug discovery specialist is the fifth biotechnology company to go public in February and priced the sector’s largest ...

US biotech Generate Biomedicines (Nasdaq: GENB) raised $400 million in its initial public offering, selling 25 million shares at $16 each, the midpoint of its range. It marks the largest biotech IPO ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Chungui International BioTech Group has filed for an initial public offering. The consumer goods company said it will sell 3 million units at $5 apiece, according to a filing with the Securities and ...

Earendil Labs, a biotechnology startup that uses artificial intelligence for drug discovery, is considering listing in Hong Kong, according to people familiar with the matter.

The developer of Covid-19 vaccine Covaxin, Bharat Biotech is considering an initial public offering that could raise over $500 million, according to sources cited by multiple reports.

Biotech IPOs fell to a decade low in 2025 Investors expect more listings amid easing rate pressure Policy clarity under Trump has reduced worst-case fears Late-stage drug pipelines drawing renewed ...

The life sciences industry is poised for an upswing in initial public offering (IPO) activity in 2026, supported by a large IPO backlog, the strong performance of biotech market indices, and positive ...

The companies Vaxcyte, Generate Biomedicines, and Immunic bagged the biggest biotech funding rounds overall in February 2026.